Endo International PLC (NASDAQ:ENDP) EVP Matthew Joseph Maletta acquired 3,000 shares of the company’s stock in a transaction dated Tuesday, August 15th. The stock was bought at an average cost of $8.02 per share, for a total transaction of $24,060.00. Following the completion of the transaction, the executive vice president now directly owns 6,984 shares of the company’s stock, valued at $56,011.68. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Endo International PLC (ENDP) traded up 6.82% during trading on Tuesday, reaching $8.14. 9,968,740 shares of the company’s stock traded hands. The stock’s market cap is $1.82 billion. The company’s 50 day moving average is $10.81 and its 200-day moving average is $11.52. Endo International PLC has a 52-week low of $7.41 and a 52-week high of $24.93.

Endo International PLC (NASDAQ:ENDP) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.19. The business had revenue of $875.73 million for the quarter, compared to the consensus estimate of $832.66 million. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The company’s revenue was down 4.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.86 earnings per share. On average, analysts anticipate that Endo International PLC will post $3.52 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was reported by Daily Political and is owned by of Daily Political. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/15/insider-buying-endo-international-plc-endp-evp-purchases-3000-shares-of-stock.html.

Several equities analysts have recently weighed in on ENDP shares. Canaccord Genuity reissued a “hold” rating and issued a $14.00 price objective on shares of Endo International PLC in a research report on Monday, April 17th. Vetr lowered shares of Endo International PLC from a “strong-buy” rating to a “hold” rating and set a $11.34 price objective on the stock. in a research report on Thursday, April 27th. BMO Capital Markets reissued a “hold” rating and issued a $15.00 price objective on shares of Endo International PLC in a research report on Monday, May 1st. Zacks Investment Research raised shares of Endo International PLC from a “sell” rating to a “hold” rating in a research report on Tuesday, May 2nd. Finally, Mizuho reissued a “buy” rating and issued a $19.00 price objective (up from $18.00) on shares of Endo International PLC in a research report on Thursday, May 25th. Three research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and five have given a buy rating to the company. Endo International PLC currently has a consensus rating of “Hold” and an average price target of $14.75.

A number of large investors have recently added to or reduced their stakes in the stock. Piedmont Investment Advisors LLC increased its stake in Endo International PLC by 43.4% in the second quarter. Piedmont Investment Advisors LLC now owns 59,211 shares of the company’s stock valued at $661,000 after buying an additional 17,928 shares during the period. Nomura Holdings Inc. acquired a new stake in Endo International PLC during the second quarter valued at approximately $745,000. Flinton Capital Management LLC increased its stake in Endo International PLC by 64.4% in the second quarter. Flinton Capital Management LLC now owns 20,400 shares of the company’s stock valued at $228,000 after buying an additional 7,990 shares during the period. Bank of Hawaii acquired a new stake in Endo International PLC during the second quarter valued at approximately $180,000. Finally, Parametric Portfolio Associates LLC increased its stake in Endo International PLC by 18.7% in the second quarter. Parametric Portfolio Associates LLC now owns 398,099 shares of the company’s stock valued at $4,447,000 after buying an additional 62,822 shares during the period. 92.27% of the stock is currently owned by institutional investors and hedge funds.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.